Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The intestinal epithelial apical junctional complex (AJC) is a specialized structure composed of tight junctions (TJs) and adherens junctions (AJs) that regulates the paracellular barrier between epithelial cells (Lee, 2015, PubMed: 25647722). Tight junctions, which include proteins such as claudins, occludin, and zonula occludens (ZO-1), act as a gatekeeper for the passage of ions, water, and solutes while preventing the entry of pathogens and toxins (Groschwitz & Hogan, 2009, PubMed: 19586907). Adherens junctions, primarily formed by E-cadherin and catenins, provide the mechanical adhesive force necessary to hold cells together and serve as a foundation for TJ assembly (Buckley & Turner, 2018, PubMed: 29146450). Disruption of these junctional proteins is a key pathological feature in diseases like inflammatory bowel disease (IBD), celiac disease, and irritable bowel syndrome (IBS), leading to increased intestinal permeability or "leaky gut" (Chelakkot et al., 2018, PubMed: 30013308). Therapeutic interventions aim to restore barrier integrity by modulating these proteins or inhibiting the signaling pathways that cause their internalization or degradation. For example, larazotide acetate is a peptide that inhibits zonulin-induced tight junction disassembly, while other agents like lubiprostone promote the assembly of these complexes through chloride channel activation (Khaleghi et al., 2021, PubMed: 33440475; Cuppoletti et al., 2012, PubMed: 22403571). Understanding the dynamics of the AJC is crucial for developing targeted therapies that can repair the intestinal barrier and mitigate chronic inflammation.
Modulation of paracellular permeability through the stabilization or assembly of tight junction and adherens junction proteins, often by antagonizing zonulin or activating chloride channels (Khaleghi et al., 2021, PubMed: 33440475; Cuppoletti et al., 2012, PubMed: 22403571).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal epithelial apical junctional complex proteins (AJC proteins).